Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21170585 | 0.75 | IMPDH2 (0.31) | IMPDH2 | |
| SCHEMBL20149540 | 0.71 | HSD17B10 (0.35) | — | |
| SCHEMBL10694680 | 0.71 | IMPDH2 (0.33) | IMPDH2 | |
| SCHEMBL31436664 | 0.71 | HSD17B10 (0.32) | — | |
| SCHEMBL20745709 | 0.70 | ALDH1A1 (0.35) | IMPDH2 | |
| SCHEMBL8072958 | 0.70 | HSD17B10 (0.34) | — | |
| SCHEMBL12348441 | 0.69 | GAA (0.31) | — | |
| SCHEMBL2493661 | 0.69 | HSD17B10 (0.39) | — | |
| SCHEMBL16059218 | 0.69 | HSD17B10 (0.39) | — | |
| SCHEMBL6075100 | 0.69 | ACHE (0.33) | IMPDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10544144-B2 | Fused pyrimidine piperidine cyclic derivative, preparation process and use thereof | SHANGHAI ALLIST PHARMACEUTICAL AND MEDICAL TECHNOL (CN) | 2020-01-28 | — | — | US | disclosed |
| US-20190218213-A1 | FUSED PYRIMIDINE PIPERIDINE CYCLIC DERIVATIVE, PREPARATION PROCESS AND USE THEREOF | SHANGHAI ALLIST PHARMACEUTICALS CO., LTD. (CN) | 2019-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190218213-A1 | FUSED PYRIMIDINE PIPERIDINE CYCLIC DERIVATIVE, PREPARATION PROCESS AND USE THEREOF | FGFR1, FGFR4, FGFR2 | IMPDH2 276/4885 |
| US-10544144-B2 | Fused pyrimidine piperidine cyclic derivative, preparation process and use thereof | FGFR1, FGFR4, FGFR2 | IMPDH2 276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.